CN103373966A - 一类4-苯胺喹唑啉类酰胺衍生物及其制备方法与用途 - Google Patents
一类4-苯胺喹唑啉类酰胺衍生物及其制备方法与用途 Download PDFInfo
- Publication number
- CN103373966A CN103373966A CN2012101111074A CN201210111107A CN103373966A CN 103373966 A CN103373966 A CN 103373966A CN 2012101111074 A CN2012101111074 A CN 2012101111074A CN 201210111107 A CN201210111107 A CN 201210111107A CN 103373966 A CN103373966 A CN 103373966A
- Authority
- CN
- China
- Prior art keywords
- quinazoline
- reaction
- preparation
- compound
- adds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- 239000003814 drug Substances 0.000 claims abstract description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- -1 4-phenylamino quinazoline ditosylate salt amide Chemical class 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 238000004440 column chromatography Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 235000015320 potassium carbonate Nutrition 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000000967 suction filtration Methods 0.000 claims description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- MGCGMYPNXAFGFA-UHFFFAOYSA-N 2-amino-5-nitrobenzonitrile Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C#N MGCGMYPNXAFGFA-UHFFFAOYSA-N 0.000 claims description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 238000011275 oncology therapy Methods 0.000 claims description 4
- VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 claims description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 3
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 229960004756 ethanol Drugs 0.000 claims description 3
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 22
- 239000000843 powder Substances 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 19
- MXNBDFWNYRNIBH-UHFFFAOYSA-N 3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1 MXNBDFWNYRNIBH-UHFFFAOYSA-N 0.000 description 19
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 11
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 11
- 235000015097 nutrients Nutrition 0.000 description 9
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 8
- BLNVISNJTIRAHF-UHFFFAOYSA-N 4-chlorobenzamide Chemical compound NC(=O)C1=CC=C(Cl)C=C1 BLNVISNJTIRAHF-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 3
- CDPKJZJVTHSESZ-UHFFFAOYSA-N 4-chlorophenylacetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C=C1 CDPKJZJVTHSESZ-UHFFFAOYSA-N 0.000 description 2
- BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 description 2
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- WXYYACUWOMKZQC-UHFFFAOYSA-N 1-benzyl-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one Chemical compound C1=CC(C(C)C)=CC=C1C(C1=CC(OCC#C)=CC=C11)=NC(=O)N1CC1=CC=CC=C1 WXYYACUWOMKZQC-UHFFFAOYSA-N 0.000 description 1
- IUJAAIZKRJJZGQ-UHFFFAOYSA-N 2-(2-chlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1Cl IUJAAIZKRJJZGQ-UHFFFAOYSA-N 0.000 description 1
- VVKCVAPLTRZJHH-UHFFFAOYSA-N 3,4-diethoxybenzoic acid Chemical compound CCOC1=CC=C(C(O)=O)C=C1OCC VVKCVAPLTRZJHH-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- JOFDSYLCZIHGGO-UHFFFAOYSA-N 4-[(4-cyclohexylphenyl)methyl-[2-[[5-(dimethylamino)naphthalen-1-yl]sulfonyl-methylamino]acetyl]amino]-2-hydroxybenzoic acid Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)N(C)CC(=O)N(C=1C=C(O)C(C(O)=O)=CC=1)CC(C=C1)=CC=C1C1CCCCC1 JOFDSYLCZIHGGO-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- AHWHROUPQPNHRI-UHFFFAOYSA-N CCOc(c(OCC)c1)ccc1C(Nc(cc12)ccc1ncnc2Nc1cc(Cl)ccc1)=O Chemical compound CCOc(c(OCC)c1)ccc1C(Nc(cc12)ccc1ncnc2Nc1cc(Cl)ccc1)=O AHWHROUPQPNHRI-UHFFFAOYSA-N 0.000 description 1
- RLSZPRPVHOOMBN-KPKJPENVSA-N CN(C)/C=N/c(ccc([N+]([O-])=O)c1)c1C#N Chemical compound CN(C)/C=N/c(ccc([N+]([O-])=O)c1)c1C#N RLSZPRPVHOOMBN-KPKJPENVSA-N 0.000 description 1
- OBPFRFGFSGUYBP-UHFFFAOYSA-N Cc1cc(Nc(c2c3)ncnc2ccc3NC(Cc(cc2)ccc2Cl)=O)ccc1 Chemical compound Cc1cc(Nc(c2c3)ncnc2ccc3NC(Cc(cc2)ccc2Cl)=O)ccc1 OBPFRFGFSGUYBP-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- UXGVSRMNSUMOGF-UHFFFAOYSA-N O=C(Cc(cc1)ccc1Br)Nc1cc2c(Nc3cc(Br)ccc3)ncnc2cc1 Chemical compound O=C(Cc(cc1)ccc1Br)Nc1cc2c(Nc3cc(Br)ccc3)ncnc2cc1 UXGVSRMNSUMOGF-UHFFFAOYSA-N 0.000 description 1
- YBDYYNNZBJDSNC-UHFFFAOYSA-N O=C(c(cc1)ccc1F)Nc(cc1)cc2c1ncnc2Nc1cc(Br)ccc1 Chemical compound O=C(c(cc1)ccc1F)Nc(cc1)cc2c1ncnc2Nc1cc(Br)ccc1 YBDYYNNZBJDSNC-UHFFFAOYSA-N 0.000 description 1
- LSKCLVPBLGFJDE-UHFFFAOYSA-N O=C(c1cccc(F)c1)Nc(cc12)ccc1ncnc2Nc1cc(Br)ccc1 Chemical compound O=C(c1cccc(F)c1)Nc(cc12)ccc1ncnc2Nc1cc(Br)ccc1 LSKCLVPBLGFJDE-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域
本发明涉及4-苯胺喹唑啉类酰胺类衍生物及其制备方法与作为潜在抗癌药物的用途。
背景技术
蛋白酪氨酸激酶(PTK)是一类具有酪氨酸激酶活性的蛋白质,可分为受体型和非受体型两种,它们能催化ATP上的磷酸基团转移到许多重要蛋白质的酪氨酸残基上,使其发生磷酸化。蛋白酪氨酸激酶在细胞内的信号转导通路中占据了十分重要的地位,调节着细胞体内生长、分化、死亡等一系列生理过程。蛋白酪氨酸激酶功能的失调则会引发生物体内的一系列疾病。已有的资料表明,超过50%的原癌基因和癌基因产物都具有蛋白酪氨酸激酶活性,酪氨酸蛋白激酶过度表达时,会阻碍细胞程序死亡,使细胞的生长调控失控,始终处于增生状态,发展成为恶性肿瘤。此外,酪氨酸基酶的异常表达还与肿瘤的侵袭和转移,肿瘤新生血管的生成,肿瘤的化疗抗性密切相关。因此,以酪氨酸激酶为靶点进行药物研发成为国际上抗肿瘤药物研究的热点。
不同配体与酪氨酸激酶结合,导致受体发生多聚化,并进一步使受体胞内区特异的受体酪氨酸残基发生自身磷酸化或交叉磷酸化,从而激活下游的信号转导通路。许多肿瘤的发生、发展都与酪氨酸激酶的异常表达有着极其密切的联系。其中与肿瘤的发生、发展最为密切,最引人注目的受体型酪氨酸激酶为表皮生长因子受体(EGFR)家族、血管内皮细胞生长因子受体(VEGFR)家族。
表皮生长因子受体(EGFR)家族广泛分布于哺乳动物的上皮细胞。临床研究表明,许多类型的实质性肿瘤都有高水平的EGFR的表达。EGFR的高度表达可以促进肿瘤细胞的增殖、血管生成、黏附、侵袭和转移,抑制肿瘤细胞的凋亡,导致肿瘤患者存活率低,预后差,疗效差,肿瘤转移可能性大,容易引起肿瘤细胞对各种细胞毒性药物的耐药性。
大多数标准的化疗药物同时杀死癌细胞和正常细胞,而表皮生长因子受体抑制剂能够针对性地附着并摧毁癌细胞,进行癌症的靶向治疗。正因为如此,EGFR 抑制剂治疗方法有更少的副作用。EGFR酪氨酸磷酸化的选择性抑制剂已成为一类重要的潜在抗癌药物。4-苯胺喹唑啉类小分子化合物是目前世界上最令人感兴趣的EGFR和VEGFR信号传递阻断试剂,也是极具潜力的抗癌新药。
酰胺类化合物因结构与人体内的小肽和多肽较为接近,被认为对药物的靶向和识别有着重要的助推作用,许多现有药物也含有酰胺的结构。
由于肿瘤复杂的形成机理,分子组合旨在阻止肿瘤的形成引起关注。一个常见的策略是将作用于不同靶点的两个具有抗癌活性的化合物通过酯键或者酰胺键组合在一起,作为一种前体药物,进入体内分解后分别作用于不同靶点。因此将4-苯胺喹唑啉类与苯甲(乙)酸以酰胺键相连,增强其抗癌活性,是很好的课题。
发明内容
本发明的目的在于提供一类4-苯胺喹唑啉类酰胺衍生物以及它们的制备方法与用途。
本发明的技术方案如下:
一类4-苯胺喹唑啉类酰胺衍生物,其特征是它有如下通式:
式中R为如下基团:
X为Cl或Br;
特别的,当R为如下基团:
X为Br;
当R为如下基团:
X为Cl。
一种制备上述的4-苯胺喹唑啉类酰胺衍生物的方法,它由下列步骤组成:
步骤1.将0.1mol 2-氰基-4-硝基苯胺缓慢加入50ml N,N-二甲基甲酰胺二甲基缩醛,在70-75℃下反应2h。反应结束后冷却至室温,析出红色固体,抽滤,乙醚洗涤。
步骤2.将0.1mol卤代苯胺加入50ml乙酸,然后缓慢加入步骤1所得产物,在70-75℃下反应1-2h,析出大量黄色固体,抽滤,先用乙酸洗涤,然后再用乙醚洗涤,烘干。
步骤3.取步骤2所得化合物2g,与140ml无水乙醇,40ml水,6ml醋酸,3g铁粉加入于500ml的烧瓶中,然后加热60-80℃回流搅拌反应5-6h,反应结束后,将反应液全部倒入500ml烧杯中,然后冷却至室温,加入40ml浓氨水搅拌。减压蒸馏除去乙醇,用乙酸乙酯萃取。萃取液拌入适量硅胶,旋干,干法上柱,乙酸乙酯∶石油醚=4∶1,柱层析,得深黄色产物。
步骤4.取取代苯甲(乙)酸1mmol加到二氯亚砜中,80℃回流4h,减压蒸干。乙酸乙酯溶解,加入步骤3制得的深黄色化合物1mmol,加入少量碳酸钾,冰浴,过夜。反应结束后,过滤除去碳酸钾,柱层析,乙酸乙酯∶石油醚=3∶1,得目标化合物。
MTT法体外抗肿瘤活性实验结果表明,本发明的新型4-苯胺喹唑啉类酰胺衍生物对人体肺癌细胞株(A549)、黑色素瘤细胞(B16-F10)和乳腺癌细胞(MCF-7)具有明显的抑制作用。因此本发明的4-苯胺喹唑啉类酰胺衍生物可以应用于制备抗癌药物。
具体实施方式
通过以下实施例进一步详细说明本发明,但本发明的范围并不受这些实施例 的任何限制。
实施例一:N-(4-((3-溴苯基)胺)喹唑啉-6-基)-3-氟苯甲酰胺(化合物1a)的制备
将0.1mol 2-氰基-4-硝基苯胺缓慢加入50ml N,N-二甲基甲酰胺二甲基缩醛,在70-75℃下反应2h。反应结束后冷却至室温,析出红色固体,抽滤,乙醚洗涤。将0.1mol间溴苯胺加入50ml乙酸,然后缓慢加入之前所得产物,在70-75℃下反应1-2h,析出大量黄色固体,抽滤,先用乙酸洗涤,然后再用乙醚洗涤,烘干。取所得化合物2g,与140ml无水乙醇,40ml水,6ml醋酸,3g铁粉加入于500ml的烧瓶中,然后加热60-80℃回流搅拌反应5-6h,反应结束后,将反应液全部倒入500ml烧杯中,然后冷却至室温,加入40ml浓氨水搅拌。减压蒸馏除去乙醇,用乙酸乙酯萃取。萃取液拌入适量硅胶,旋干,干法上柱,乙酸乙酯∶石油醚=4∶1,柱层析,得深黄色产物N4-(3-溴苯基)喹唑啉-4,6-二胺。取150mg间氟苯甲酸,加到8ml二氯亚砜中,80℃回流4h,减压蒸干。乙酸乙酯溶解,加入1mmol深黄色化合物N4-(3-溴苯基)喹唑啉-4,6-二胺,加入少量碳酸钾,冰浴,过夜。反应结束后,过滤除去碳酸钾,柱层析,乙酸乙酯∶石油醚=3∶1,得目标化合物。白色粉末,产率90%,Mp 250-252℃;1H NMR(300MHz,DMSO-d6,δppm):7.28-7.43(m,4H),7.59-7.66(m,1H),7.75(t,J=3.00Hz,1H),7.85(t,J=5.09Hz,2H),7.76(dd,J1=8.97Hz,J2=8.97Hz,1H),8.17(s,1H),8.31(s,1H),8.61(s,1H),8.90(s,1H),9.98(s,1H),10.74(s,1H).ESI-MS:438.2(C21H15BrFN4O[M+H]+).Anal.Calcd for C21H14BrFN4O:C,57.68%;H,3.23%;N,12.81%.Found:C,60.01%;H,3.52%;N,13.22%.
实施例二:N-(4-((3-溴苯基)胺)喹唑啉-6-基)-4-氟苯甲酰胺(化合物2a)的制备
制备方法同实施例一。以对氟苯甲酸酸代替间氟苯甲酸,得到目标化合物。白色粉末,产率93%,Mp 274-276℃;1H NMR(300MHz,DMSO-d6,δppm):7.28-7.45(m,4H),7.82-7.91(m,2H),8.03(dd,J1=8.97Hz,J2=8.97Hz,1H),8.16-8.20(m,3H),8.62(s,1H),8.90(s,1H),9.94(s,1H),10.62(s,1H).ESI-MS:438.2(C21H15BrFN4O[M+H]+).Anal.Calcd for C21H14BrFN4O:C,57.68%;H,3.23%;N,12.81%.Found:C,57.23%;H,3.54%;N,13.21%.
实施例三:N-(4-((3-溴苯基)胺)喹唑啉-6-基)-4-硝基苯甲酰胺(化合物3a)的制备
制备方法同实施例一。以对硝基苯甲酸代替间氟苯甲酸,得到目标化合物。白色粉末,产率92%,Mp 237-239℃;1H NMR(300MHz,DMSO-d6,δppm):7.28-7.45(m,4H),7.82-7.91(m,2H),8.03(dd,J1=8.97Hz,J2=8.97Hz,1H),8.16-8.20(m,3H),8.62(s,1H),8.90(s,1H),9.94(s,1H),10.62(s,1H).ESI-MS:464.3(C21H15BrN5O3,[M+H]+).Anal.Calcd for C21H14BrN5O3:C,54.33%;H,3.04%;N,15.08%.Found:C,54.63%;H,3.34%;N,14.69%.
实施例四:N-(4-((3-溴苯基)胺)喹唑啉-6-基)-2-甲基苯甲酰胺(化合物4a)的制备
制备方法同实施例一。以邻甲基苯甲酸代替间氟苯甲酸,得到目标化合物。白色粉末,产率92%,Mp 252-254℃;1H NMR(300MHz,DMSO-d6,δppm):2.46(s,3H,-CH3),7.29-7.79(m,4H),7.44(t,J=3.93Hz,1H),7.53(d,J=1.29Hz,1H),7.80-7.88(m,2H),7.95(d,J=8.97,1H),8.32(s,1H),8.60(s,1H),9.97(s,1H),8.93(s,1H),10.65(s,1H).ESI-MS:434.3(C22H18BrN4O,[M+H]+).Anal.Calcd for C22H17BrN4O:C,60.98%;H,3.95%;N,12.93%.Found:C,60.57%;H,4.25%;N,12.53%.
实施例五:N-(4-((3-溴苯基)胺)喹唑啉-6-基)-2-(4-氯苯基)乙酰胺(化合物5a)的制备
制备方法同实施例一。以对氯苯乙酸代替间氟苯甲酸,得到目标化合物。白色粉末,产率91%,Mp 251-253℃;1H NMR(300MHz,DMSO-d6,δppm):3.76(s,2H),7.26-7.76(m,2H),7.41(s,4H),7.78-7.89(m,3H),8.14(s,1H),8.58(s,1H),8.71(d,J=0.15Hz,1H),9.90(s,1H),10.54(s,1H).ESI-MS:468.8(C22H17BrClN4O,[M+H]+).Anal.Calcd for C22H16BrClN4O:C,56.49%;H,3.45%;N,11.98%.Found:C,56.73%;H,3.47%;N,12.05%.
实施例六:N-(4-((3-溴苯基)胺)喹唑啉-6-基)-2-(4-溴苯基)乙酰胺(化合物6a)的制备
制备方法同实施例一。以对溴苯乙酸代替间氟苯甲酸,得到目标化合物。白色粉末,产率93%,Mp 256-258℃;1H NMR(300MHz,DMSO-d6,δppm):3.74(s,2H),7.27-7.41(m,4H),7.55(d,J=8.25Hz,2H),7.78-7.89(m,3H),8.14(s,1H),8.58(s,1H),8.71(d,J=1.43Hz,1H),9.90(s,1H),10.53(s,1H).ESI-MS:513.2(C22H17Br2N4O,[M+H]+).Anal.Calcd for C22H16Br2N4O:C,51.59%;H,3.15%;N,10.94%.Found:C,51.67%;H,3.14%;N,11.03%.
实施例七:N-(4-((3-溴苯基)胺)喹唑啉-6-基)-2-(4-氟苯基)乙酰胺(化合物7a)的制备
制备方法同实施例一。以对氟苯乙酸代替间氟苯甲酸,得到目标化合物。淡黄色粉末,产率88%,Mp 214-216℃;1H NMR(300MHz,DMSO-d6,δppm):7.18(t,J=4.48Hz,2H),7.26-7.33(m,2H),7.36-7.44(m,2H),7.78-7.89(m,3H),8.14(s,1H),8.57(s,1H);8.72(s,1H),9.89(s,1H),10.52(s,1H).ESI-MS:523.0(C22H17BrFN4O,[M+H]+).Anal.Calcd for C22H16BrFN4O:C,52.70%;H,3.08%;N,10.69%.Found:C,52.43%;H,3.36%;N,10.89%.
实施例八:N-(4-((3-溴苯基)胺)喹唑啉-6-基)吡啶酰胺(化合物8a)的制备
制备方法同实施例一。以吡啶-2-甲酸代替间氟苯甲酸,得到目标化合物。白色粉末,产率87%,Mp 263-264℃;1H NMR(300MHz,DMSO-d6,δppm):7.27-7.38(m,2H),7.72(t,J=6.12Hz,1H),7.83(d,J=8.97Hz,1H),7.9(d,J=7.86Hz,1H),8.11(t,J=7.68Hz,1H),8.22(d,J=7.86Hz,2H),8.34(dd,J1=9.15Hz,J2=8.97Hz,1H),8.60(s,1H),8.77(d,J=4.74Hz,1H),8.88(s,1H),9.87(s,1H),10.90(s,1H)..ESI-MS:421.3(C20H15BrN5O,[M+H]+).Anal.Calcd for C20H14BrN5O:C,57.16%;H,3.36%;N,16.66%.Found:C,57.27%;H,3.56%;N,16.52%.
实施例九:N-(4-((3-溴苯基)胺)喹唑啉-6-基)苯甲酰胺(化合物9a)的制备
制备方法同实施例一。以苯甲酸代替间氟苯甲酸,得到目标化合物。黄色粉末,产率93%,Mp 275-276℃;1H NMR(300MHz,DMSO-d6,δppm):7.28-7.38(m,2H),7.55-7.64(m,3H),7.82-7.91(m,2H),8.04(t,J=3.57Hz,3H),8.20(s,1H),8.92(s,1H),9.93(s,1H),10.61(s,1H).ESI-MS:420.2(C21H16BrN4O,[M+H]+).Anal.Calcd for C21H15BrN4O:C,60.16%;H,3.61%;N,13.36%.Found:C,60.26%;H,3.35%;N,13.17%.
实施例十:N-(4-((3-溴苯基)胺)喹唑啉-6-基)-4-氯苯甲酰胺(化合物10a)的制备
制备方法同实施例一。以对氯苯甲酸代替间氟苯甲酸,得到目标化合物。黄色粉末,产率93%,Mp 244-246℃;1H NMR(300MHz,DMSO-d6,δppm):7.07(d,J=8.4Hz,2H),7.30-7.43(m,3H),7.72-7.86(m,2H),8.04(d,J=8.4Hz,1H),8.11(d,J=8.4Hz,1H),8.18(s,1H,NH),8.63(s,1H),8.78(s,1H),10.82(s,1H),11.54(s,1H,NHCO).ESI-MS:454.7(C21H14BrClN4O,[M+H]+).Anal.Calcd for C21H14BrClN4O:C,55.59%;H,3.11%;N,12.35%.Found:C,55.72%;H,3.18%;N,12.14%.
实施例十一:N-(4-((3-溴苯基)胺)喹唑啉-6-基)-2-(3-氯苯基)乙酰胺(化合物11a)的制备
制备方法同实施例一。以间氯苯乙酸代替间氟苯甲酸,得到目标化合物。淡黄色粉末,产率90%,Mp 269-271℃;1H NMR(300MHz,DMSO-d6,δppm):3.78(s,2H),7.27-7.42(m,5H),7.47(s,1H),7.78-7.89(m,3H),8.14(s,1H),8.58(s,1H),8.73(s,1H),9.92(s,1H),10.56(s,1H).ESI-MS:468.8(C22H17BrClN4O,[M+H]+).Anal.Calcd for C22H16BrClN4O:C,56.49%;H,3.45%;N,11.98%.Found:C,56.73%;H,3.49%;N,12.04%.
实施例十二:N-(4-((3-氯苯基)胺)喹唑啉-6-基)-4-氟苯甲酰胺(化合物1b)的制备
制备方法同实施例一。以对氟苯甲酸和对氯苯胺分别代替间氟苯甲酸和对溴苯胺,得到目标化合物。白色粉末,产率89%,Mp 284-285℃;1H NMR(300MHz,DMSO-d6,δppm):7.16(d.J=9.12Hz,1H),7.29-7.45(m,3H),7.84(d,J=8.79Hz,2H),8.02(d,J=8.97Hz,1H),8.08-8.16(m,3H),8.62(s,1H),8.89(s,1H),9.95(s,1H),10.63(s,1H).ESI-MS:393.8(C21H15ClFN4O,[M+H]+).Anal.Calcd for C21H14ClFN4O:C,64.21%;H,3.59%;Cl,9.03%;F,4.84%;N,14.26%;O,4.07%.Found:C,64.21%;H,3.59%;N,14.26%.
实施例十四:N-(4-((3-氯苯基)胺)喹唑啉-6-基)-4-硝基苯甲酰胺(化合物2b)的制备
制备方法同实施例一。以对硝基苯甲酸和对氯苯胺分别代替间氟苯甲酸和对溴苯胺,得到目标化合物。黄色粉末,产率92%,Mp 319-321℃;1H NMR(300MHz,DMSO-d6,δppm):7.17(d,J=7.32Hz,1H),7.42(t,J=4.02Hz,1H),7.85(t,J=4.48Hz,2H),8.05(t,J=3.02Hz,2H),8.17(d,J=8.58Hz,1H),8.30(t,J=6.40Hz,3H),8.43(d,J=8.58Hz,2H),8.63(s,1H),8.91(s,1H),9.96(s,1H),10.92(s,1H).ESI-MS:420.8(C21H15ClN5O3,[M+H]+).Anal.Calcd for C21H14ClN5O3:C,60.08%;H,3.36%;N,16.68%.Found:C,60.32%;H,3.34%;N,16.71%.
实施例十五:N-(4-((3-氯苯基)胺)喹唑啉-6-基)-2-甲基苯甲酰胺(化合物3b)的制备
制备方法同实施例一。以邻甲基苯甲酸和对氯苯胺分别代替间氟苯甲酸和对溴苯胺,得到目标化合物。淡黄色粉末,产率90%,Mp 252-254℃;1H NMR(300MHz,DMSO-d6,δppm):2.45(s,3H,-CH3),7.32-7.47(m,4H),7.50-7.57(m,2H),7.70(d,J=8.67Hz,1H),7.89(t,J=1Hz,1H),8.06(d,J=8.97Hz,1H),8.16(dd,J1=9.12Hz,J2=8.94Hz,1H),8.90(s,1H),9.22(s,1H),10.94(s,1H),11.58(s,1H).ESI-MS:389.9(C22H18ClN4O,[M+H]+).Anal.Calcd for C22H17ClN4O:C,67.95%;H,4.41%;N,14.41%.Found:C,68.03%;H,4.40%;N,14.45%.
实施例十六:2-(4-氯苯基)N-(4-((3-氯苯基)胺)喹唑啉-6-基)-乙酰胺(化合物4b)的制备
制备方法同实施例一。以对氯苯乙酸和对氯苯胺分别代替间氟苯甲酸和对溴苯胺,得到目标化合物。淡黄色粉末,产率90%,Mp 314-315℃;1H NMR(300MHz,DMSO-d6,δppm):3.79(s,2H),7.14(d,J=6.96Hz,1H),7.41(s,6H),7.77(d,J=7.50Hz,2H),7.98(d,J=11.54Hz,2H),8.56(s,1H),8.74(s,1H),10.01(s,1H),10.97(s,1H).ESI-MS:424.2(C22H16C]2N4O,[M+H]+).Anal.Calcd for C22H16Cl2N4O:C,62.42%;H,3.81%;N,13.24%.Found:C,62.82%;H,3.81%;N,13.24%.
实施例十七:2-(4-溴苯基)-N-(4-((3-氯苯基)胺)喹唑啉-6-基)-乙酰胺(化合物5b)的制备
制备方法同实施例一。以对溴苯乙酸和对氯苯胺分别代替间氟苯甲酸和对溴苯胺,得到目标化合物。白色粉末,产率93%,Mp 255-257℃;1H NMR(300MHz,DMSO-d6,δppm):3.73(s,2H),7.14(d,J=9.15Hz,1H),7.33-7.41(m,3H),7.55(d,J=8.22Hz,2H),7.79(d,J=9.15Hz,2H),7.87(d,J=10.95Hz,1H),8.02(s,1H),8.57(s,1H),8.71(s,1H),9.89(s,1H),10.53(s,1H).ESI-MS:468.8(C22H17BrClN4O,[M+H]+).Anal.Calcd for C22H16BrClN4O:C,56.49%;H,3.45%;N,11.98%.Found:C,56.61%;H,3.62%;N,11.88%.
实施例十八:2-(4-氟苯基)-N-(4-((3-氯苯基)胺)喹唑啉-6-基)-乙酰胺(化合物6b)的制备
制备方法同实施例一。以对氟苯乙酸和对氯苯胺分别代替间氟苯甲酸和对溴苯胺,得到目标化合物。黄色粉末,产率90%,Mp 248-250℃;1H NMR(300MHz,DMSO-d6,δppm):3.76(s,2H),7.15-7.24(m,3H),7.43(t,J=3.2Hz,3H),7.73(d,J =8.22Hz,1H),7.84(d,J=8.97Hz,1H),7.94(d,J=6.75Hz,2H),8.68(s,1H),8.83(s,1H),10.44(s,1H),10.71(s,1H).ESI-MS:407.8(C22H17ClFN4O,[M+H]+).Anal.Calcd for C22H17ClFN4O:C,64.95%;H,3.96%;N,13.77%.Found:C,64.95%;H,3.96%;N,13.77%.
实施例十九:N-(4-((3-氯苯基)胺)喹唑啉-6-基)吡啶酰胺(化合物7b)的制备
制备方法同实施例一。以吡啶-2-甲酸和对氯苯胺分别代替间氟苯甲酸和对溴苯胺,得到目标化合物。白色粉末,产率90%,Mp 281-283℃;1H NMR(300MHz,DMSO-d6,δppm):7.17(d,J=8.61Hz,1H),7.43(t,J=4.03Hz,1H),7.72-7.76(m,1H),7.85(d,J=8.97Hz,2H),8.10-8.16(m,2H),8.24(d,J=7.68Hz,1H),8.37(dd,J1=8.97Hz,J2=9.15Hz,1H),8.63(s,1H),8.80(d,J=4.56Hz,1H),8.91(d,J=2.01Hz),9.91(s,1H),10.92(s,1H).ESI-MS:376.8(C20H15ClN5O,[M+H]+).Anal.Calcd for C20H14ClN5O:C,63.92%;H,3.75%;N,18.64%.Found:C,64.02%;H,3.85%;N,17.96%.
实施例二十:N-(4-((3-氯苯基)胺)喹唑啉-6-基)-3,4-二乙氧基苯甲酰胺(化合物8b)的制备
制备方法同实施例一。以3,4-二乙氧基苯甲酸和对氯苯胺分别代替间氟苯甲酸和对溴苯胺,得到目标化合物。白色粉末,产率91%,Mp 279-281℃;1H NMR(300MHz,DMSO-d6,δppm):3.68(m,4H),4.00(m,6H),6.90(s,2H),7.00(s,1H),7,37(d,J=7.32Hz,1H),7.50(t,J=4.11Hz,1H),7.64(d,J=8.04Hz,1H),7.85(s,1H),7.94(d,J=8.97Hz,1H),8.05(d,J=9.15Hz,1H),8.88(s,1H),9.01(s,1H),10.84(s,1H),11.37(s,1H).ESI-MS:463.9(C25H23ClN4O3,[M+H]+).Anal.Calcd for C25H23ClN4O3:C,64.86%;H,5.01%;N,12.10%.Found:C,64.94%;H,5.21%;N,12.08%.
实施例二十四:新型4-苯胺喹唑啉类酰胺衍生物的体外抗肿瘤活性研究
采用MTT[3-(4,5)-双甲基-2-噻唑-(2,5)-苯基溴化四氮唑蓝]法来测定4-苯胺喹唑啉类酰胺衍生物对人体肺癌细胞株(A549)、黑色素瘤细胞(B16-F10)和乳腺癌细胞(MCF-7)的抑制率,计算IC50值(μM)。
(1)培养液(每升)的配制:①悬浮细胞:RPMI-1640培养粉一袋(10.4g),新生牛血清100ml,青霉素溶液(20万U/ml)0.5ml,链霉素溶液(20万U/ml)0.5ml,加三蒸水溶解后,用5.6%的NaHCO3溶液调PH值至7.2-7.4,最后定容至1000ml。过滤灭菌。②贴壁细胞:同上,再加入NaHCO32.00g,HEPES2.38g。
(2)D-Hanks缓冲液(每升)的配制:NaCl 8.00g,KCl 0.40g,Na2HPO4·12H2O 0.06g,KH2PO40.06g,NaHCO30.35g。高压灭菌。
(3)胰蛋白酶液的配制:利用D-Hanks缓冲液配成浓度为0.5%胰蛋白酶液。过滤除菌。
(4)实验药液的配制:将测试样品用少量的三蒸水溶解配成储备液,一般按实验最高浓度的10倍配制储备液。根据化合物溶解性不同,可用三蒸水直接溶解,或用少量DMSO助溶,再加三蒸水溶解。DMSO在培养液中的浓度不宜过大,加药后的每孔细胞悬液中DMSO的终浓度一般不超过0.05%-0.1%。储备液保存于-20℃冰箱中备用。
(5)人肺癌细胞A549的培养:为悬浮生长细胞,常规培养于RPMI-1640培养液内(含10%小牛血清、100U/ml链霉素),置于37℃、5%CO2培养箱中 培养,每隔3-4天传代一次。传代时将原瓶中培养液转移至离心管中,1000rpm离心5min,弃去原培养液,加入等量新鲜培养液,吹打均匀,移取适量至新鲜培养瓶中,再补充新鲜培养液至原体积(培养液体积约为培养瓶容量的1/10)。
(6)人体口腔上表皮癌细胞KB的培养:为贴壁生长细胞,常规培养于RPMI-1640培养液内(含10%小牛血清、100U/ml链霉素),置37℃、5%CO2培养箱中培养,每隔3-4天传代一次。传代时先弃去原培养液,再用D-Hanks缓冲液洗涤;然后用0.5%胰蛋白酶消化30秒左右,加入少量新鲜培养液终止消化;吹打,使贴壁细胞从培养瓶壁上脱落下来;移取适量至新鲜培养瓶中,再补充新鲜培养液至原体积(培养液体积约为培养瓶容量的1/10)。
(7)细胞孵育:取对数生长期的2种肿瘤细胞,调细胞悬液浓度为1-1.5×105个ml-1。在96孔培养板中每孔加细胞悬液100μl,置37℃,5%CO2培养箱中培养24h。培养24h后,分别按设计加入药液。
(8)加药:将测试药液按照最终浓度的浓度梯度分别加入到各个孔中,每个浓度设6个平行孔。实验分为药物试验组(分别加入不同浓度的测试药)、对照组(只加培养液和细胞,不加测试药)和空白组(只加培养液,不加细胞和测试药)。将加药后的96孔板置于37℃,5%CO2培养箱中培养48h。阳性对照药物的活性按照测试样品的方法测定。
(9)存活细胞的测定:在培养了48h后的96孔板中,每孔加MTT 40μl(用D-Hanks缓冲液配成4mg/ml)。在37℃放置4h后,移去上清液。每孔加150μl DMSO,振荡5min,使formazan结晶溶解。最后,利用自动酶标仪在570nm波长处检测各孔的光密度(OD值)。
抑制率的计算:细胞生长的抑制率按照下列公式计算:
生长抑制率=(1-存活率)×100%=[1-(OD实验-OD空白)/(OD对照-OD空白)]×100%(OD实验表示测试药物组的平均光密度,OD对照表示对照组的平均光密度,OD空白表示对照组的平均光密度)。
半数抑制浓度(IC50)定义为当50%的肿瘤细胞存活时的药物浓度。根据测定的光密度(OD值),制作细胞生长抑制率的标准曲线,在标准曲线上求得其对应的药物浓度。
测得的三种癌细胞抗增殖活性IC50见表1所示
Claims (3)
2.一种制备权利要求1所述的4-苯氨基喹唑啉类酰胺衍生物的方法,它由下列步骤组成:
步骤1.将0.1mol 2-氰基-4-硝基苯胺缓慢加入50ml N,N-二甲基甲酰胺二甲基缩醛,在70-75℃下反应2h。反应结束后冷却至室温,析出红色固体,抽滤,乙醚洗涤。
步骤2.将0.1mol卤代苯胺加入50ml乙酸,然后缓慢加入步骤1所得产物,在70-75℃下反应1-2h,析出大量黄色固体,抽滤,先用乙酸洗涤,然后再用乙醚洗涤,烘干。
步骤3.取步骤2所得化合物2g,与140ml无水乙醇,40ml水,6ml醋酸,3g铁粉加入于500ml的烧瓶中,然后加热60-80℃回流搅拌反应5-6h,反应结束后,将反应液全部倒入500ml烧杯中,然后冷却至室温,加入40ml浓氨水搅拌。减压蒸馏除去乙醇,用乙酸乙酯萃取。萃取液拌入适量硅胶,旋干,干法上柱,乙酸乙酯∶石油醚=4∶1,柱层析,得深黄色产物。
步骤4.取取代苯甲(乙)酸1mmol加到二氯亚砜中,80℃回流4h,减压蒸干。乙酸乙酯溶解,加入步骤3制得的深黄色化合物1mmol,加入少量碳酸钾,冰浴,过夜。反应结束后,过滤除去碳酸钾,柱层析,乙酸乙酯∶石油醚=3∶1,得目标化合物。
3.权利要求1所述的4-苯氨基喹唑啉类酰胺衍生物在制备抗癌药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012101111074A CN103373966A (zh) | 2012-04-17 | 2012-04-17 | 一类4-苯胺喹唑啉类酰胺衍生物及其制备方法与用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012101111074A CN103373966A (zh) | 2012-04-17 | 2012-04-17 | 一类4-苯胺喹唑啉类酰胺衍生物及其制备方法与用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103373966A true CN103373966A (zh) | 2013-10-30 |
Family
ID=49459853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012101111074A Pending CN103373966A (zh) | 2012-04-17 | 2012-04-17 | 一类4-苯胺喹唑啉类酰胺衍生物及其制备方法与用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103373966A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457105A (en) * | 1992-01-20 | 1995-10-10 | Zeneca Limited | Quinazoline derivatives useful for treatment of neoplastic disease |
-
2012
- 2012-04-17 CN CN2012101111074A patent/CN103373966A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457105A (en) * | 1992-01-20 | 1995-10-10 | Zeneca Limited | Quinazoline derivatives useful for treatment of neoplastic disease |
Non-Patent Citations (1)
Title |
---|
HUAN-QIU LI ET AL: "Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity", 《BIOORGANIC & MEDICINAL CHEMISTRY》, vol. 20, 6 November 2011 (2011-11-06), pages 317 - 323 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103664787B (zh) | 炔杂芳环化合物及其应用 | |
AU2004230928B2 (en) | Tie-2 modulators and methods of use | |
CN103848829A (zh) | 杂芳基炔烃化合物及其应用 | |
KR20130091331A (ko) | 함질소 방향족 복소환 유도체 | |
IL213141A (en) | Dihydroindane amides for use in regulating protein kinase activity | |
CN105980377B (zh) | 作为egfr-t790m激酶抑制剂的取代的嘧啶类化合物 | |
CN104844580A (zh) | 嘧啶类化合物、其制备方法及医药用途 | |
CN103130792A (zh) | 一种2-氨基噻唑类化合物 | |
CN101503402B (zh) | 2-苯胺嘧啶衍生物及其制备和用途 | |
WO2021017996A1 (zh) | 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途 | |
CN106831780A (zh) | 具有cdk4/6和hdac抑制活性的新型杂环衍生物 | |
CN106146412B (zh) | 喹唑啉衍生物及其制备方法和应用 | |
CN103058938A (zh) | 4-苯胺喹唑啉类和取代肉桂酸的复合物及其制备方法与用途 | |
CN102421754B (zh) | 丙烯酰胺类衍生物及其制备药物的用途 | |
CN110511218A (zh) | 一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途 | |
CN105061441A (zh) | 含哌嗪等氮杂环的香豆素并吡唑类化合物及其制备与在抑制肿瘤细胞中的应用 | |
CN104854088B (zh) | 用于治疗癌症、病毒感染和肺病的新型吲哚衍生物 | |
CN103373966A (zh) | 一类4-苯胺喹唑啉类酰胺衍生物及其制备方法与用途 | |
CN104262263A (zh) | 一种N,6二苯基嘧啶-4-胺类Bcr-Abl抑制剂及其制备方法和应用 | |
CN104860890A (zh) | T790m突变型egfr的抑制剂及其在制备抗肿瘤药物中的应用 | |
CN103121991A (zh) | 一种芳基羧酸类伊马替尼衍生物及其制备和用途 | |
CN102002044A (zh) | 嘌呤-8-酮类及噻唑并嘧啶类衍生物及其制备方法和医药用途 | |
CN107501283B (zh) | 取代芳甲杂基取代苯胺基缩乙二醇醚环代喹唑啉的制备及肿瘤治疗药物应用 | |
CN101723894B (zh) | N-喹啉酰胺类衍生物及其制法与用途 | |
CN103709146B (zh) | 一类含苯并咪唑结构的喹啉-4-胺衍生物、其制法及医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131030 |